Press archive
03/11/10, General Medicine FDA Grants Orphan Drug Status to Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis Berlin, March 11, 2010 – Bayer Schering Pharma AG, Germany, announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for the ciprofloxacin... more
03/10/10, Research & Development MR contrast agents for diagnosis of breast cancer Bayer starts Phase III study to evaluate efficacy and safety of Gadovist® in magnetic resonance mammography more
02/26/10, Company Bayer successful in a difficult environment Group sales EUR 31,168 million (minus 5.3 percent) / EBITDA before special items EUR 6,472 million (minus 6.6 percent) / Net income EUR 1,359 million (minus 20.9 percent) / Net cash flow significantl... more
02/18/10, Research & Development VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema Statistically significant improvement in vision achieved over 24 weeks / Results to be presented at the Angiogenesis 2010 – Clinical Trials meeting in Miami, Florida on February 20, 2010 more
01/25/10, Hemophillia Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis Study will not be able to meet primary endpoint / Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development more
01/12/10, Diagnostic Imaging Bayer Schering Pharma receives green light from European authorities to use Gadovist® 1.0 in children Berlin, January 12, 2010 – Bayer Schering Pharma AG successfully completed the procedure for securing approval to use the contrast medium Gadovist® 1.0 in children aged seven and above in Euro... more
12/10/09, Research & Development Clinical Programs with Riociguat in Pulmonary Hypertension Well on Track Encouraging top-line data from the first Phase II study in pulmonary hypertension owing to interstitial lung disease (PH-ILD) / First Phase II study in pulmonary hypertension owing to chronic obstruc... more
12/07/09, Women’s Healthcare Visanne® cleared for market launch in Europe as new treatment option for endometriosis Berlin, December 7, 2009 – Bayer Schering Pharma AG, Germany, has successfully completed the decentralized part of drug approval procedure in Europe for a new treatment of endometriosis called ... more
12/06/09, Thrombosis Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE Impressive 82% Relative Risk Reduction (RRR) in the Recurrence of Symptomatic VTE over Patients Treated with Placebo / Positive Benefit-Risk profile for Rivaroxaban Confirmed / First Phase III Data i... more
12/02/09, Xarelto Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President German Federal President Horst Köhler praises outstanding innovation achievement / Development of the novel oral anticoagulant rivaroxaban commended more
12/02/09, Diabetes Flying off cliffs and reaching for the stars Type 1 diabetic Chris Southwell relies on BREEZE® 2 to live his snowboarding dream more
12/01/09, Oncology Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy Development of new BiTE antibody for treatment of solid tumors more
12/01/09, Multiple sclerosis Bayer’s Betaferon® approved in China for Treatment of Multiple Sclerosis Launch planned by mid 2010 more
11/30/09, Research & Development Bayer Starts Phase III Trial with Florbetaben Detection of beta-Amyloid plaques in Alzheimer patients possible / Florbetaben could improve current diagnostic tools more
11/26/09, Contour Diabetes experts underline benefits of SMBG for all types of treatment plans Individual target setting and postprandial testing are key to optimal diabetes management more
11/19/09, Xarelto Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009 Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE more
11/11/09, Worldnews Improving the care of people with diabetes Primary and secondary prevention of diabetes / Focusing on self-care, environment, nutrition, therapy, and exercise more
11/11/09, Company Self-determined Family planning: worldwide initiative for maternal health and against child mortality A new Bayer HealthCare initiative with the motto “Family planning” will concentrate the company’s activities in developing countries, which have been running for 40 years now, and e... more
11/11/09, Company Healthcare: Fight against Neglected Diseases As part of its societal responsibilities, Bayer HealthCare puts special emphasis on therapies for the so-called neglected diseases. More than 3.3 billion people, half of the world’s population,... more
11/11/09, Company Data and Facts: “Family planning” Pregnancies Out of an estimated 210 million pregnancies per year world-wide, 38% are unplanned and about 20% end in abortion. The overwhelming majority of these abortions occur in developing countrie... more
Search
Page tools
click to adjust font size
Social Bookmarks
